FierceBiotechOriginal article
{"a":[{"_":"J&J axes eye disease gene therapy after key phase 2b readout","$":{"href":"/biotech/jj-axes-eye-disease-gene-therapy-after-key-phase-2b-readout","hreflang":"en"}}]}
Phase 2negativeNegative
AI Analysis
Summary
Johnson & Johnson has terminated development of an eye disease gene therapy following a negative phase 2b readout, a key milestone expected in 2026.
Clinical Trial Data
Phase
2b
Primary Endpoint
Not Met
Outcome Details
Development stopped after phase 2b readout
Importance:6/10
Sentiment:
-0.80
gene therapyphase 2bprogram terminationeye diseaseclinical development
Related Companies
Read the original article
Published by FierceBiotech on July 15, 2026 10:27 AM